Interchangeability or substitution of biosimilars

Biosimilars/Research | Posted 27/05/2011 post-comment0 Post your comment

The interchangeability or substitution of biosimilars is a subject that differs somewhat between Europe and the US. These different approaches to biosimilars are discussed by Dr Mark McCamish and Dr Gillian Woollett in their published paper [1].

picture31

In the EU, EMA does not have the authority to designate biosimilars as being interchangeable with the reference product.

In the US, however, the Biologics Price Competition and Innovation Act gives the FDA the authority to designate a biosimilar as interchangeable with its reference product. This means that the biosimilar may be substituted for the originator product by the pharmacist without reference to the prescribing physician.

This automatic substitution, the authors feel, would enable biosimilars to be adopted much more rapidly. Thus increasing access for patients to these often life-changing medicines and reducing healthcare costs for both patients and governments.

According to Dr McCamish and Dr Woollett, a biosimilar product for which comparability is demonstrated should be interchangeable with its comparator, as is the case for conventional generics.

Related articles

Need for a global pathway for biosimilars

Regulatory approach to biosimilar development

Opportunities for biosimilar development

Comparability for biosimilar development

Worldwide biosimilar development

Global biosimilar market to grow to US$3.7 billion in 2015

US guidelines for biosimilars

US healthcare reform

Reference

1. McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3(2):209-17. doi:10.4161/mabs.3.2.15005

comment icon Comments (0)
Post your comment
Related content
Biosimilars: Promises made. Promises kept?
ST002293
Biosimilars/Research Posted 19/11/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010